News

The U.S. Food and Drug Administration (FDA) issued a Warning Letter to a Chinese company based on a review of records. Key issues include failure to adequately test the identity of incoming components, lack of process validation, and inadequate laboratory testing of finished drug products.

More

At the beginning of July, the FDA published a Warning Letter due to a lack of chemical and microbiological controls in the manufacture of a product for dermal application and inadequate testing of the ingredients used.

More

The FDA rarely goes into great detail about expected measures in its Warning Letters, especially not when it comes to instructions on the desired procedure. This is now different in a Warning Letter that was published in July. It describes in considerable detail what the FDA considers to be appropriate CAPA measures in a specific case.

More

In June 2024, the U.S. FDA issued a Warning Letter to the Portuguese company "Fancystage Unipessoal, LDA" after having inspected its site in January 2024. According to U.S. FDA Warning Letter, the firm failed to do proper incoming control tests to identity the goods.

More

"Warning Letters" for FDA: Two recent letters from Congress to the FDA Commissioner highlight ongoing and historical challenges within the FDA's foreign drug inspection program, even raising concerns about inspector competence.

More

The U.S. Food and Drug Administration (FDA) has issued a Warning Letter to a Chinese drug manufacturing facility for significant CGMP violations. Among other issues, the firm performed in-house HPLC testing for internal use without audit trails and could not provide validation reports for these methods. Additionally, the company failed to adequately explain the purpose of this testing.

More

During an FDA inspection of an Indian pharmaceutical manufacturer, residues were found in non-dedicated manufacturing equipment. The manufacturer had tried to rule out possible cross-contamination by testing retained samples. Read here why this is not sufficient for the FDA.

More

The FDA's Center for Drug Evaluation and Research (CDER) has compiled a 10-point overview of how it fulfils its task of ensuring the quality of medicinal products. What are these 10 points?

More

Two reports were recently published showing that the FDA is once again carrying out more inspections. And this is also happening in the EU - despite the MRA.

More

The nine-day FDA inspection of an Indian pharmaceutical manufacturer had already taken place in October 2023. Due to the numerous and, as the FDA itself writes, egregious GMP violations and the inadequate response to the list of deficiencies by the manufacturer, a Warning Letter has now been issued.

More
x
Search